ANG LI to Thrombosis
This is a "connection" page, showing publications ANG LI has written about Thrombosis.
Connection Strength
2.686
-
External validation of a novel electronic risk score for cancer-associated thrombosis in a comprehensive cancer center. Am J Hematol. 2023 07; 98(7):1052-1057.
Score: 0.561
-
Derivation and Validation of a Clinical Risk Assessment Model for Cancer-Associated Thrombosis in Two Unique US Health Care Systems. J Clin Oncol. 2023 06 01; 41(16):2926-2938.
Score: 0.551
-
Cost-effectiveness analysis of low-dose direct oral anticoagulant (DOAC) for the prevention of cancer-associated thrombosis in the United States. Cancer. 2020 04 15; 126(8):1736-1748.
Score: 0.449
-
Cost effectiveness analysis of direct oral anticoagulant (DOAC) versus dalteparin for the treatment of cancer associated thrombosis (CAT) in the United States. Thromb Res. 2019 Aug; 180:37-42.
Score: 0.427
-
Direct oral anticoagulant (DOAC) versus low-molecular-weight heparin (LMWH) for treatment of cancer associated thrombosis (CAT): A systematic review and meta-analysis. Thromb Res. 2019 01; 173:158-163.
Score: 0.393
-
Clinical and genetic markers of vascular toxicity in glioblastoma patients: Insights from NRG Oncology RTOG-0825. Neuro Oncol. 2025 Mar 07; 27(3):767-778.
Score: 0.160
-
Development and validation of a risk model for hospital-acquired venous thrombosis: the Medical Inpatients Thrombosis and Hemostasis study. J Thromb Haemost. 2024 02; 22(2):503-515.
Score: 0.146